Cyclarity Therapeutics
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Cardiovascular
At Cyclarity Therapeutics, our mission is to develop therapeutics which target the root cause of diseases of aging - the accumulation of toxic biomolecules over time. Our lead drug candidate is UDP-003, a small molecule which targets and removes toxic oxidized cholesterol, a core driver of plaque formation in cardiovascular disease and dysfunction in other chronic diseases. We recently completed our first in human phase 1 healthy normal volunteer clinical trial for our lead drug candidate, UDP-003, in Adelaide, Australia in partnership with the Victorian Heart Hospital and under the supervision of Dr. Stephen Nicholls, the leading expert in blood vessel plaque formation and treatment. Results established that UDP-003 is safe for humans and notably demonstrated target engagement. A phase 1b trial in patients with atherosclerotic plaque burden is ongoing, aiming to demonstrate safety in unhealthy patients. We are currently raising a $40M series B round to fun phase 2 clinical trials.
Company HQ City:
Novato
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2019
Lead Product in Development:
Cyclarity's lead product is a small molecule drug designed to target oxidized cholesterol for the treatment of atherosclerosis and related cardiovascular diseases. This drug's potential applications extend to additional disease of aging indications including metabolic-associated fatty liver diseases and neurodegenerative diseases.
CEO
Co-Founder, CEO of Scientific Affairs: Matthew O'Connor
Co-Founder, CEO of Corporate Affairs: Mike Kope
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
We expect this catalyst update to occur in Q1 of 2027.
What is your next catalyst (value inflection) update?
Our next value inflection point will be the completion of phase 1b clinical trials, which will provide confirmation of safety in patients with atherosclerotic plaque burden and potentially provide preliminary data on efficacy.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}